A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America
1
Issued Date
2025-01-01
Resource Type
eISSN
2234943X
Scopus ID
2-s2.0-105021333655
Journal Title
Frontiers in Oncology
Volume
15
Rights Holder(s)
SCOPUS
Bibliographic Citation
Frontiers in Oncology Vol.15 (2025)
Suggested Citation
Chiang C.L., Soo R.A., Mok T., Voon P.J., Thamlikitkul L., Cheng Y., Horinouchi H., Cho B.C., Xu K.L., Ahn M.J. A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America. Frontiers in Oncology Vol.15 (2025). doi:10.3389/fonc.2025.1646608 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113100
Title
A comparison of clinical guidelines, treatment characteristics and outcomes in small cell lung cancer between East Asia and Europe/North America
Author's Affiliation
National Yang-Ming University Taiwan
Samsung Medical Center, Sungkyunkwan university
Taipei Veterans General Hospital
Siriraj Hospital
National Cancer Center Hospital
National University Hospital
Amgen Incorporated
Chinese University of Hong Kong, Faculty of Medicine
Yonsei Cancer Hospital
Sarawak General Hospital
Jilin Cancer Hospital
Samsung Medical Center, Sungkyunkwan university
Taipei Veterans General Hospital
Siriraj Hospital
National Cancer Center Hospital
National University Hospital
Amgen Incorporated
Chinese University of Hong Kong, Faculty of Medicine
Yonsei Cancer Hospital
Sarawak General Hospital
Jilin Cancer Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a poor prognosis and accounts for approximately 11% of all lung cancers. Owing to the complex and aggressive nature of the disease, clinical management of SCLC is challenging. Many SCLC regional guidelines, including those from East Asia, have been developed in light of potential regional variations in socioeconomic conditions and healthcare infrastructure. However, less is known about the potential implications of the inherent population/regional differences in clinical management and the emerging treatment landscape in SCLC. Here, we review variations in the real-world patient characteristics and in diagnosis and treatment guidelines in SCLC between East Asia and Europe/North America. We also consider similarities and differences in real-world treatment patterns, as well as clinical outcomes between regions, to explore the need to adapt clinical management in SCLC.